Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications
Open Access
- 25 June 2012
- journal article
- review article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 4 (7) , 545-556
Abstract
Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post‐translational modifications controlling virtually all cellular processes. What was once regarded as a mere signal for protein degradation has turned out to be a major regulator of molecular signalling networks. Deregulation of ubiquitin signalling is closely associated with various human pathologies. Here, we summarize the current knowledge of ubiquitin signalling in immune deficiencies and cancer as well as the available therapeutic strategies targeting the ubiquitin system in combating these pathogenic conditions.Keywords
Funding Information
- Funded Access
This publication has 123 references indexed in Scilit:
- cIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by cFLIP IsoformsMolecular Cell, 2011
- Pattern Recognition Receptors and InflammationCell, 2010
- USP10 Regulates p53 Localization and Stability by Deubiquitinating p53Cell, 2010
- A Role for Ubiquitin in Selective AutophagyMolecular Cell, 2009
- Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and FunctionCancer Cell, 2009
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- Ubiquitination Regulates PTEN Nuclear Import and Tumor SuppressionCell, 2007
- NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTENCell, 2007
- Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic ApproachCell, 2006